3.06 USD
▼-0.10-3.16%
盘后 3.04 -0.65%
2026-11-20
市值
$26.83M
市盈率
—
EPS
-6.81
股息率
—
52 周区间
2.60 – 13.09
成交量
109.66K
Beta
1.66
目标价
—
52W 低 2.6052W 高 13.09
价格走势
公司简介
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore Co...